Kymera Therapeutics (KYMR) Scheduled to Post Earnings on Thursday

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) is set to release its earnings data before the market opens on Thursday, October 31st. Analysts expect Kymera Therapeutics to post earnings of ($0.83) per share for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.10. The company had revenue of $25.60 million for the quarter, compared to analyst estimates of $12.55 million. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The business's quarterly revenue was up 55.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.67) earnings per share. On average, analysts expect Kymera Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kymera Therapeutics Stock Performance

Shares of KYMR stock traded down $0.03 on Thursday, hitting $48.73. The stock had a trading volume of 282,022 shares, compared to its average volume of 602,248. The stock's 50 day moving average is $46.77 and its 200-day moving average is $40.11. The firm has a market capitalization of $2.99 billion, a price-to-earnings ratio of -19.41 and a beta of 2.21. Kymera Therapeutics has a 52-week low of $9.60 and a 52-week high of $53.27.

Insider Activity

In other news, Director Pamela Esposito sold 13,500 shares of the company's stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of the business's stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $49.10, for a total transaction of $245,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Pamela Esposito sold 13,500 shares of the firm's stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The disclosure for this sale can be found here. Company insiders own 15.82% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on KYMR. B. Riley raised their target price on Kymera Therapeutics from $31.00 to $36.00 and gave the company a "neutral" rating in a research note on Tuesday, July 9th. Leerink Partners restated an "outperform" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research note on Monday, September 9th. Leerink Partnrs raised Kymera Therapeutics to a "strong-buy" rating in a research report on Monday, September 9th. Morgan Stanley raised their price target on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 14th. Finally, Oppenheimer lifted their price target on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an "outperform" rating in a research note on Friday, September 27th. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $49.00.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.